pharmaphorum

MAY 31, 2023

PM Society’s ‘Securing Market Access to Medicines for England, Ireland, Scotland & Wales’ – part one Mike.Hammerton Wed, 05/31/2023 - 12:45 Bookmark this

97

97

Pharmaceutical Technology

JULY 20, 2023

Ahead of APEC’s "Rare disease vision 2025" deadline, Asian countries are working at different speeds towards improving drug market access.

75

75

pharmaphorum

MAY 6, 2022

For life science companies around the world, enabling faster access to innovative drugs and therapies is a complicated challenge. Combination pricing: access to the future of oncology treatment. Read Deep Dive: Market Access in full. The post Deep Dive: Market Access appeared first on.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

MARCH 1, 2021

In the latest of a suite of features looking at the biggest markets in Europe, Leela Barham takes stock of what 2021 could bring for market access in France. The draft includes simplification of early access to new medicines aiming to make access faster and more attractive to companies. About the author.

Labelling 78

Labelling 78

Drug Channels

MARCH 28, 2024

Bill discusses specialty therapy access barriers, including payer utilization management techniques and “no coverage” policies. Today’s guest post comes from Bill Dupere, SVP of Product Development & Partnerships at Mercalis. Contact Mercalis to learn about their Patient Support Services. Read on for Bill’s insights.

81

81

pharmaphorum

FEBRUARY 23, 2021

The market access landscape in Germany is particularly interesting in 2021, as a key component – AMNOG – is ten years old, and that milestone prompts reflections on what has worked well and what needs reform. The AMNOG (Act on the Reform of the Market for Medicinal Products) was implemented on the 1 January 2011.

Biosimilars 90

Biosimilars Medical Records 90

Express Pharma

NOVEMBER 1, 2023

With the approval, ImmunoACT is set to lead the journey of indigenous CAR-T cell therapy in the country, but the drug is expected to face market access challenges in India, says GlobalData. This might increase medical tourism to India by providing access to exclusive therapy at a very low cost.

88

88

Drug Channels

OCTOBER 8, 2021

Today’s guest post comes from Bill Dupere, Practice Lead and VP of Market Access Solutions and Eric Willis, VP of Operations Hub and Reimbursement Services at TrialCard. Bill and Eric discuss the complexities of digital patient support program technologies and introduce TrialCard’s integrated suite of solutions.

Specialty Pharmacies 90

Specialty Pharmacies 90

PharmExec

JANUARY 26, 2023

As pharmaceutical market access teams head into 2023, these ten trends detail why evolved preparation, thought, and engagement will be needed to meet post-pandemic marketplace expectations.

52

52

pharmaphorum

APRIL 1, 2022

However, while this dramatic shake-up of the UK Market Access environment aims to improve care for patients and providers for life science companies, this unfamiliar territory presents both opportunities and challenges. The post ICSs – an opportunity to improve Patient & Market Access at a local level appeared first on.

98

98

PharmExec

APRIL 7, 2023

Fingerpaint Group further enforces its commitment to the space, marking its second market access acquisition in three years.

52

52

PharmExec

APRIL 18, 2023

German laws, European VBCs, and trends in China, Brazil, and Saudi Arabia are changing the way global market access works.

52

52

pharmaphorum

JUNE 21, 2022

Whether it’s the levelling up agenda, economics, social care and population health management and more, ICSs are front and centre of everything,” Steven Ferguson, head of Market Access UK and Ireland, IQVIA. The post ICSs: improving patient and market access at a local level appeared first on.

52

52

BioPharma Dive

MAY 15, 2023

Using labs and claims data, pharma companies can uncover new opportunities to improve market access for patients.

55

55

pharmaphorum

JUNE 8, 2022

The move marks the largest expansion of FH to date and allows clients to benefit from integrated offerings spanning policy, access, value, and evidence. The addition of Avalere’s more than 200 advisors deepens FH’s US market presence and diversifies its customer base. We are excited to welcome Avalere to FH.” .

Communication 52

Communication 52

pharmaphorum

MAY 5, 2023

Securing Market Access to Medicines for England, Ireland, Scotland Wales – The Landscape Ahead Mike.Hammerton Fri, 05/05/2023 - 07:20 Bookmark this

52

52

Pharmaceutical Technology

AUGUST 8, 2023

Pricing and reimbursement of pharmaceuticals is changing in Sweden, with prices lower than average as a result of growing cost containment strategies. Here’s what you need to know.

52

52

pharmaphorum

AUGUST 17, 2023

War in the Blood: The battle takes shape in the burgeoning European oncology CAR-T market access space Mike.Hammerton Thu, 17/08/2023 - 09:00 Bookmark this

52

52

Pharmafile

FEBRUARY 28, 2023

Published date: 28/02/2023 Summary: Terebellum, subsidiary of global specialty pharmacy and healthcare solutions organisation AscellaHealth, is launching a strategic guide to help manufacturers bring rare disease products to market. read more

Specialty Pharmacies 40

Specialty Pharmacies 40

Pharmaceutical Commerce

OCTOBER 5, 2022

Wednesday, October 5, 2022, 11am EDT Market access considerations can be complex to navigate and overwhelming to address for biopharmaceutical commercial teams launching their first specialty drug. Get answers to eleven key questions that will help guide commercial teams in effectively launching specialty products.

52

52

pharmaphorum

AUGUST 25, 2021

Jirair Ratevosian, executive director of global patient solutions and government affairs at Gilead Sciences, tells us how his company utilised previously developed partnerships and their knowledge of providing global access to HIV treatments to distribute Remdesivir. Government partnerships are crucial to accessibility.

Packaging 52

Packaging Compounding Labelling 52

STAT

FEBRUARY 14, 2024

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. health care system could lose up to  $133 billion  in savings and leave patients without access to the medicines they need.

Biosimilars 350

Biosimilars 350

PharmExec

OCTOBER 18, 2022

Commercial Health Insurance may bring more opportunities for market access in China.

52

52

PharmExec

MAY 10, 2023

BCG’s 2022 benchmark study uncovers new competencies needed for pharma access leaders in enterprise-wide business strategy, where thoughtfully designed approaches and goals focused on shared priority and responsibility are increasingly important.

116

116

STAT

DECEMBER 18, 2023

Declan gets the medicine through a special access program called compassionate use, but the company that developed the drug may soon walk away from the project if it fails to win approval to market its medicine — meaning Declan would lose access to it. Continue to STAT+ to read the full story…

Hospitals 358

Hospitals 358

pharmaphorum

JUNE 12, 2017

Market access is influencing drug development and commercial launch strategy more than ever before, with 85% of prescription drugs in the United States reimbursed through managed care plans.

Drug Development 52

Drug Development 52

STAT

SEPTEMBER 29, 2023

A handful of the largest purveyors of generic medicines have made only halting progress to ensure their drugs are accessible for patients in low- and middle-income countries, a new analysis found.

Generic Medicine 286

Generic Medicine 286

pharmaphorum

FEBRUARY 19, 2021

Ashfield Advisory , part of UDG Healthcare plc, today announced the acquisition of PHMR Limited, a Market Access Consultancy and specialist in Health Economics and Outcomes Research (HEOR). The post UDG Healthcare acquires market access, HEOR specialist, PHMR Limited as Ashfield Advisory appeared first on.

52

52

STAT

MARCH 14, 2024

WASHINGTON — Novo Nordisk’s newly won permission to market the heart benefits of its obesity drug Wegovy could provide a backdoor way to expand access to the drug for people on Medicare, experts told STAT. Currently, Medicare is prohibited by law from covering medications for obesity treatment alone.

Labelling 363

Labelling 363

Drug Channels

JUNE 21, 2023

Four crucial trends will deflate the gross-to-net bubble—thereby disrupting market access strategies, altering pharmacy benefit manager (PBM) profit models, and changing plan sponsor benefit designs. Our latest data appear below. Perhaps it’s time to get ready for the day when SpongeBob SquarePants will depart from Drug Channels.

61

61

Drug Channels

APRIL 4, 2023

Four crucial trends will deflate the gross-to-net bubble—thereby disrupting market access strategies, altering pharmacy benefit manager (PBM) profit models, and changing plan sponsor benefit designs. Our latest data appear below. Perhaps it’s time to get ready for the day when SpongeBob SquarePants will depart from Drug Channels.

58

58

STAT

MARCH 13, 2024

health care market, this often isn’t the case. In the courses I teach, I expound on the importance of complete and accurate information about prices and quality in well-functioning markets. Yet in the U.S. Prices are both high and highly variable as well as difficult to observe. I’m an economics professor.

Grocery Stores 291

Grocery Stores Hospitals 291

Drug Patent Watch

JANUARY 21, 2021

The post Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions appeared first on DrugPatentWatch - Make Better Decisions. Highlights….

52

52

PharmExec

JULY 27, 2022

Using data visualizations to improve access to payers.

96

96

PharmExec

NOVEMBER 14, 2022

The move reflects Fingerpaint Group's commitment to innovate its capabilities as clients' needs evolve.

52

52

STAT

SEPTEMBER 26, 2023

Extending patent protection doesn’t just stretch a drug’s profits — in some cases, doing so can lead to its most significant revenue period, according to a recent analysis published by the Initiative for Medicines, Access & Knowledge, or I-MAK, a nonprofit advocating for drug pricing reforms.

Drug Pricing 355

Drug Pricing Biosimilars Drug Development 355

STAT

APRIL 11, 2024

The European Parliament has voted overwhelmingly to adopt legislation that is supposed to transform the way medicines are brought to market and accessed across much of Europe. But the effort — which must still be approved by the European Council — drew mixed reactions from the pharmaceutical industry and consumer groups.

323

323